Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
S Hao, S Xu, L Li, Y Li, M Zhao, J Chen, S Zhu, Y Xie… - BMC cancer, 2022 - Springer
Background: Antibodies and derivative drugs targeting immune checkpoints have been
approved for the treatment of several malignancies, but there are fewer responses in …
approved for the treatment of several malignancies, but there are fewer responses in …
Generating a bispecific antibody drug conjugate targeting PRLR and HER2 with improving the internalization
HF Zong, BH Zhang, JW Zhu - Pharmaceutical Fronts, 2022 - thieme-connect.com
Antibody drug conjugate (ADC) therapy has become one of the most promising approaches
in cancer immunotherapy. The bispecific targeting could improve the specificity, affinity, and …
in cancer immunotherapy. The bispecific targeting could improve the specificity, affinity, and …